HER2 低表达乳癌 - 研发管线分析：2023 年

HER2-Low Breast Cancer- Pipeline Analytics 2023

出版日期: 2023年09月22日 | 出版商:

Mellalta Meets LLP | 英文 180 Pages | 商品交期: 5-7个工作天内

价格

简介目录

目前，超过50%的乳癌被定义为“人类表皮生长因子受体2（HER2）-低乳癌（BC）”，HER2免疫组织化学（IHC）评分为+1或+2，萤光原位杂交（FISH）检测结果为阴性。随着越来越多的公司寻求在 HER2 低表达肿瘤中开发和商业化治疗性 ADC，不断变化的治疗模式正在为市场创造新的机会。

目前，HER2 低乳癌产品线中有超过 33 个候选药物正在临床和临床前研究中进行评估。市场的主要参与者包括江苏恆瑞医药、Duuality Biologics、烟台荣昌製药、吉利德科学、阿斯特捷利康/第一三共等，它们拥有强大的 HER2 低表达乳癌候选药物临床管线。

本报告调查了全球 HER2-low 乳癌市场，涵盖了按开发阶段划分的管道产品分析、按阶段划分的竞争格局、公司、治疗领域和适应症。它还提供当前的市场机会、市场驱动因素/挑战等。

The “HER2-Low Breast Cancer -Pipeline Analytics -2023” report published by Mellalta Meets covers the HER2-Low Breast Cancer Therapies market opportunity providing Key Competitive Analysis, 30+ Companies with Pipeline Drug Profiles, Clinical Trials, Other Developments (Collaboration Details, Funding, etc.), Licensing and Agreements, Business Agreement, Business Partner as well as Clinical Partner. Reports cover pipeline product analysis by stage of development, competitive landscape by phases, companies, therapy area and indication by phases. HER2-Low Metastatic Breast Cancer reports add value in terms of providing the description of clinical-stage products with respect to their clinical & regulatory timelines as well as in terms of providing the current market opportunity, drivers and challenges.

The introduction of HER2-low breast cancer represents a significant shift in the understanding and treatment of breast cancer. More than 50% of breast cancers are currently defined as "Human epidermal growth factor receptor 2 (HER2) low breast cancer (BC)", with HER2 immunohistochemistry (IHC) scores of +1 or +2 with a negative fluorescence in situ hybridization (FISH) test. The changing treatment landscape has created new opportunities in the market for more companies to develop and commercialize the use of therapeutic ADCs in HER2-low tumors.

In this report, Mellalta Meets provides an in-depth analysis of the HER2-Low Breast Cancer Pipeline covering preclinical and clinical studies, details of partnerships and business deal values, targeted technologies and therapy areas, investments, and acquisition trends. Currently, there are more than 33+ candidates in the HER2-Low Breast Cancer Pipeline under evaluation in clinical and preclinical studies. The major key players operating in the market are Jiangsu HengRui Medicine, Duality Biologics, Yantai Rongchang Pharmaceutical, Gilead Sciences, AstraZeneca/Daiichi Sankyo and many more which have robust clinical pipeline of HER2-Low Breast Cancer candidates.

As per analysis, the development pipeline is full of different ADCs and combination approaches which can help in addressing this new subtype of Breast cancer.

Mellalta's HER2-Low Breast Cancer Pipeline Report- Market Summary

Report Attributes	Details
Key Late Stage Market Players:	Jiangsu HengRui Medicine; Duality Biologics; Yantai Rongchang Pharmaceutical; Gilead Sciences; AstraZeneca/Daiichi Sankyo.
Lead Assets:	Phase 3 (10+); Phase 2 (10+); Phase 1 (5+); Preclinical (3+); Discovery stages.

Mellalta's HER2-Low Breast Cancer Pipeline Report - Key Highlights

There are ~10 products in the Phase 3 stage of development, representing ~35% of the total share of the developing HER2-Low Breast Cancer Therapeutics landscape.

The pipeline of HER2-Low Breast Cancer therapies is dominated by the Phase III (10+) assets; Phase II (10+); Phase I (5+) and Preclinical (3+) and Discovery assets.

To be continued…

Report Coverage:

Indication Prioritization: HER2-Low Breast Cancer market potential based on Indications

Business Transactions & Strategies: Key collaborations and deal values

HER2-Low Breast Cancer Pipeline Development: Product Profiles, Clinical Trials & Results

HER2-Low Breast Cancer Acquisition Targets

HER2-Low Breast Cancer Competitive Intelligence

Recent and upcoming events

Table of Content

1. REPORT OVERVIEW

2. OVERVIEW

2.1. HER2-Low Breast Cancer - Overview
2.2. Diagnostic tools for HER2-Low Breast Cancer
2.3. AI-based HER2-low IHC scoring in breast cancer
2.4. Diagnostic tools for HER2-Low Breast Cancer detection: Limitations
2.5. Current Challenges with HER2-Low Breast Cancer

3. HER2-LOW BREAST CANCER PIPELINE ANALYSIS

3.1. Overview
3.2. Assets by Indication/Phase
3.3. Pipeline Products by Stage of Development
3.4. HER2-Low Breast Cancer Competitive Landscape
3.5. Pipeline Products by Company and Phases
3.6. HER2-Low Breast Cancer Clinical & Regulatory Timelines

4. HER2-LOW BREAST CANCER ACQUISITIONS, LICENSING AND COLLABORATION DEALS

4.1. HER2-Low Breast Cancer Acquisitions, Licensing and Deal values
4.2. HER2-Low Breast Cancer Acquisitions, Licensing by Transaction type and total amount size by Phases
4.3. Promising Technologies Under development

5. HER2-Low Breast Cancer PIPELINE LANDSCAPE

5.1. Profile at Glance
5.2. Late-Stage Assets Comparisons At-a-glance
5.3. HER2-Low Breast Cancer Pipeline Drug Profiles
- 5.3.1. Phase III
  - 5.3.1.1. Duality Biologics: DB-1303
    - 5.3.1.1.1. Product Profile & Description
    - 5.3.1.1.2. Collaborations
    - 5.3.1.1.3. Other Developments
    - 5.3.1.1.4. Clinical Trials
  - 5.3.1.2. Jiangsu HengRui Medicine: Trastuzumab rezetecan
    - 5.3.1.2.1. Product Profile & Description
    - 5.3.1.2.2. Collaborations
    - 5.3.1.2.3. Other Developments
    - 5.3.1.2.4. Clinical Trials
  - 5.3.1.3. RemeGen/Seagen: Disitamab vedotin
    - 5.3.1.3.1. Product Profile & Description
    - 5.3.1.3.2. Collaborations
    - 5.3.1.3.3. Other Developments
    - 5.3.1.3.4. Clinical Trials
    - 5.3.1.3.5. Others…
  - 5.3.1.4. Phase II
    - 5.3.1.4.1. Miracogen: MRG002
      - 5.3.1.4.1.1. Product Profile & Description
      - 5.3.1.4.1.2. Collaborations
      - 5.3.1.4.1.3. Other Developments
      - 5.3.1.4.1.4. Clinical Trials
    - 5.3.1.4.2. Merus: MCLA-128
      - 5.3.1.4.2.1. Product Profile & Description
      - 5.3.1.4.2.2. Collaborations
      - 5.3.1.4.2.3. Other Developments
      - 5.3.1.4.2.4. Clinical Trials
      - 5.3.1.4.2.5. Others…
    - 5.3.1.4.3. Phase I
      - 5.3.1.4.3.1. Sichuan Baili Pharmaceutical/SystImmune: BL-M07D1
      - 5.3.1.4.3.2. Product Profile & Description
      - 5.3.1.4.3.3. Collaborations
      - 5.3.1.4.3.4. Other Developments
      - 5.3.1.4.3.5. Clinical Trials
    - 5.3.1.4.4. HighField Biopharmaceuticals Corporation: HF158K1
      - 5.3.1.4.4.1. Product Profile & Description
      - 5.3.1.4.4.2. Collaborations
      - 5.3.1.4.4.3. Other Developments
      - 5.3.1.4.4.4. Clinical Trials
      - 5.3.1.4.4.5. Others…